{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:13:47Z","timestamp":1788952427799,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperphosphatemia is a recognized on\u2010target adverse event of\u00a0erdafitinib, a pan\u2013fibroblast growth factor receptor (pan\u2010FGFR) tyrosine kinase\u00a0inhibitor with Food and Drug Administration approval to treat advanced urothelial cell carcinoma with FGFR2\/3 mutations. This study hypothesized that\u00a0hyperphosphatemia is a biomarker for drug activity and is associated with\u00a0improved overall survival (OS) and other oncologic end points in phase 2\/3 clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the phase 2 BLC2001 and cohorts 1 and 2 of the phase 3 THOR clinical trials were pooled; only patients who received erdafitinib were included. Kaplan\u2013Meier and Cox proportional hazards models were used to examine the effect of hyperphosphatemia (as classified by Common Terminology Criteria for Adverse Events [CTCAE] grade) on OS, progression\u2010free survival (PFS), and objective response rate (ORR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 409 subjects (median age, 66 years; interquartile range, 60\u201372 years) who met the inclusion criteria were pooled from the THOR and BLC2001\u00a0clinical trials, of whom 78.4% had hyperphosphatemia. Subjects with CTCAE grade 3+ hyperphosphatemia had improved OS (hazard ratio [HR],\u00a00.21; 95% CI, 0.05\u20130.86;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.031) and PFS (HR,\u00a00.16; 95% CI, 0.04\u20130.67;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.012) in multivariable Cox proportional hazards models compared to patients without hyperphosphatemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this secondary analysis of the BLC2001 and THOR trials, higher CTCAE hyperphosphatemia grades were associated with improved OS, PFS, and ORR. These findings suggest that hyperphosphatemia may serve as a potential biomarker of erdafitinib activity, and warrant prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70480","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:51:44Z","timestamp":1780573904000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between hyperphosphatemia and overall survival among patients with advanced urothelial cancer treated with erdafitinib in phase 2\/3 clinical trials"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-3823","authenticated-orcid":false,"given":"Denzel","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Urology University of Rochester Medical Center  Rochester New\u00a0York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Steidle","sequence":"additional","affiliation":[{"name":"Department of Urology University of Rochester Medical Center  Rochester New\u00a0York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences University of Rochester Medical Center  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Urology University of Rochester Medical Center  Rochester New\u00a0York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6296-2473","authenticated-orcid":false,"given":"Brendan J.","family":"Guercio","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Department of Medicine University of Rochester Medical Center  Rochester New\u00a0York USA"},{"name":"Wilmot Cancer Institute University of Rochester Medical Center  Rochester New\u00a0York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jathin","family":"Bandari","sequence":"additional","affiliation":[{"name":"Department of Urology University of Rochester Medical Center  Rochester New\u00a0York USA"},{"name":"Wilmot Cancer Institute University of Rochester Medical Center  Rochester New\u00a0York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Malshy","sequence":"additional","affiliation":[{"name":"Department of Urology University of Rochester Medical Center  Rochester New\u00a0York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2011.12.001"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgi290"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00660\u20104"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.003"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2013.01.024"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147845"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12727"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201023\u20102646"},{"key":"e_1_2_9_12_1","article-title":"Package Insert","author":"Balversa (Erdafitinib)","year":"2019","journal-title":"Janssen Pharmaceutical Companies"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201018\u20103334"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.013"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.966900"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.5009"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.002"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30109\u20101"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13552"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/po\u201024\u201000896"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2025.09.004"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70480","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:34:28Z","timestamp":1788950068000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,15]]}},"alternative-id":["10.1002\/cncr.70480"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70480","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"2026-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70480"}}